ESC-HFA 2024: Late-Breaking Science Video Collection
Published: 14 May 2024
-
Views:
1374
-
Likes:
7
-
Views:
1374
-
Likes:
7
-
Up Next
-
7m 19s
-
5m 24sPart 2 | Session 4 Timing of Cardio-Kidney Protection with SGLT2i
-
2m 54s
-
4m 46s
-
4m 40sPart 2 | Session 7 FINE-HEART: Design & Baseline Characteristics
-
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Harriette Van Spall, Mark Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study Harriette Van Spall, Jasper J Brugts
-
12m 4sPart 1 | Session 3 Late-Breaker Discussion: Insights from the STEP-HFpEF Harriette Van Spall, Mikhail Kosiborod
-
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF Harriette Van Spall, Tauben Averbuch
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT Nicolas Girerd
Overview
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.
PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure patients. The Cordella device is a novel system for monitoring ambulatory pulmonary artery pressure. The device comes packaged with a broader range of home disease management monitoring systems, including access to vital signs including weight, blood pressure and heart rate.
Key findings showed that the Cordella system was safe in regard to freedom from device implant complications and sensor failure (<1%). The device was also found to be effective in regard to event rates.
Interview Questions:
- What are the unmet needs of NYHA Class III Patients?
- Could you tell us more about the Cordella sensor system?
- What is the patient population and study design?
- What are your key findings?
- What are your take-home messages?
- What further study is needed?
Recorded on-site at HFA 2024, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Editor: Jordan Rance
Videographer: Tom Green, Oliver Miles
Comments